AMPH: שווי חברה לרווח נקי Amphastar

The historical P/E chart for Amphastar Pharmaceuticals (AMPH) demonstrates earnings valuation dynamics, where 12.10 becomes the new value for this metric. Glucagon sales and the integration of Baqsimi support the growth in market capitalization. Brand stability is based on the quality of complex injectable systems. Nasal glucagon and generics provide the current effect while the market awaits approval of new inhalation lines.

Sales of flagship drugs and the launch of high-margin generics by Amphastar Pharmaceuticals (AMPH) directly determine net income, which serves as the denominator when calculating the stock's market value. By analyzing the issuer's P/E ratio, an investor assesses the payback period for investments through the lens of current earnings, where extreme values on the chart signal either overvalued assets or hidden structural business risks.